GLP-1 Generics (2026): When Will Wegovy, Ozempic, Mounjaro & Zepbound Go Generic? Patent Cliff Tracker

Short answer: two generic GLP-1 receptor agonists are already FDA-approved in the US — Hikma generic liraglutide referencing Victoza (December 2024, type 2 diabetes) and Teva generic liraglutide 3 mg referencing Saxenda (August 28, 2025, chronic weight management). Amneal's generic exenatide referencing Byetta was also approved (November 21, 2024), but AstraZeneca discontinued the Byetta brand in October 2024, so the practical retail impact is limited. The high-volume franchises — Wegovy, Ozempic, Rybelsus (semaglutide, Novo Nordisk), Mounjaro, Zepbound (tirzepatide, Eli Lilly), and Foundayo (orforglipron, Eli Lilly) — remain patent-protected, with composition-of-matter exclusivity widely modeled in the early 2030s for semaglutide and the mid-to-late 2030s for tirzepatide and orforglipron. Trulicity (dulaglutide, Eli Lilly) is the regulatory exception: it is an Fc-fusion biologic on a BLA, so follow-on dulaglutide would be a biosimilar (351(k) pathway), not a Hatch-Waxman generic. None has been FDA-approved as of 2026-05-09. This is the verified per-drug patent-cliff timeline.

What “generic GLP-1” actually means (NDA vs BLA pathways)

Before any timeline makes sense, the regulatory pathway has to be clear. There are two distinct FDA follow-on approval routes, and they apply to different GLP-1 drugs:

• Hatch-Waxman generic pathway (ANDA, 351(j) of the FD&C Act). Used for small-molecule drugs and for chemically synthesized peptides regulated under a New Drug Application (NDA). The follow-on filer demonstrates bioequivalence to the reference listed drug; FDA can approve the generic as therapeutically equivalent (AB rated) and pharmacists can substitute it. This is the pathway used for the Hikma and Teva liraglutide generics, the Amneal exenatide generic, and — eventually — for any generic semaglutide, tirzepatide, or orforglipron.
• Biosimilar pathway (BLA, 351(k) of the PHS Act). Used for follow-on biologics — recombinant proteins, monoclonal antibodies, and Fc-fusion proteins. The follow-on filer demonstrates that the candidate biosimilar is “highly similar” to the reference biologic with no clinically meaningful differences. Biosimilarity is not the same as interchangeability. A biosimilar can only be substituted at the pharmacy counter without prescriber action if FDA has separately granted it interchangeable status under section 351(k)(4). This is the pathway that would apply to follow-on Trulicity (dulaglutide) — it is an Fc-fusion biologic, not a synthesized peptide — and as of 2026-05-09 no biosimilar dulaglutide has been approved.

So when somebody asks “when will Trulicity go generic?” the technically correct answer is: it won't. Trulicity will eventually have biosimilars, not generics. The distinction matters because biosimilars carry a different cost-erosion curve than small-molecule generics (typical biosimilar list-price discount is 30-50% off the reference biologic in the first years; small-molecule generics typically erode 80-90% of brand price within 24 months of multiple generic launches).

Already approved (2024-2025): three generic GLP-1s on the US market

Three GLP-1 receptor agonists already have FDA-approved generics in the US, all approved within a 9-month window in 2024-2025. These are the precedent set for what every later GLP-1 generic timeline will look like.

Why these three first: liraglutide and exenatide are the oldest GLP-1 receptor agonists in the US. Byetta was first approved in 2005, Victoza in 2010, Saxenda in 2014. Their composition-of-matter patents had run long enough that the first ANDA filers could clear the FDA Orange Book patent listings without resorting to design-around or method-of-use carve-outs that would block weight-management labeling. The Saxenda generic is particularly notable as the first FDA-approved generic GLP-1 RA for chronic weight management in the US — a meaningful precedent for the cash-pay obesity market.

Practical impact in 2026: the Hikma Victoza generic is the principal cost-relief story. Generic liraglutide 1.8 mg pen-injectors are now substantially cheaper than brand Victoza for type 2 diabetes patients. The Teva Saxenda generic launched too recently for full retail-pricing data to settle, but expect a parallel pattern. The Amneal Byetta generic is largely historical — AstraZeneca discontinued the Byetta brand on October 25, 2024, before the generic launched, so there is no large reference-brand market for the generic to disrupt.

Patent cliff timeline (per drug)

The remaining branded GLP-1 receptor agonists fall into three regulatory buckets: synthesized peptides on NDAs (semaglutide, tirzepatide), small-molecule oral on an NDA (orforglipron), and one Fc-fusion biologic on a BLA (dulaglutide). Every date below is a best-available public estimate. The actual generic / biosimilar launch date can differ by years in either direction depending on patent-term extensions, pediatric exclusivity, paragraph-IV litigation, and settlement agreements.

Every cell labeled “estimate” should be treated as a working best-available public number, not a guaranteed date. The authoritative sources to confirm any specific date are the FDA Orange Book (for patent and exclusivity listings on NDA drugs), the FDA Purple Book (for biologic exclusivity on BLA drugs), USPTO Public Patent Search (for the underlying composition-of-matter and method-of-use patent expirations), and each manufacturer's annual report (Novo Nordisk Form 20-F, Eli Lilly Form 10-K) where management discusses material patent expirations under the “risk factors” or “intellectual property” headings.

Semaglutide (Ozempic, Wegovy, Rybelsus) — early 2030s

Semaglutide is a 31-amino-acid synthesized peptide modified with a fatty-acid side chain for albumin binding. It is regulated under three separate NDAs: Ozempic (subcutaneous once-weekly, type 2 diabetes), Wegovy (subcutaneous once-weekly 2.4 mg, chronic weight management), and Rybelsus (oral daily, type 2 diabetes). All three rely on the same composition-of-matter patents, but Wegovy and Rybelsus add formulation patents (Wegovy: dose strength and pen device; Rybelsus: SNAC absorption-enhancer co-formulation, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate).

The composition-of-matter patent on semaglutide is widely modeled to expire in the early 2030s based on its 2007 filing plus standard 20-year patent term plus the 5-year Hatch-Waxman patent-term extension Novo Nordisk has obtained for at least one Orange Book-listed patent. The 6-month pediatric exclusivity available for FDA-approved pediatric trial completion can push that further. The SNAC formulation patent and pen-device patents on Wegovy may run beyond the core composition-of-matter patent, which is why Ozempic and Wegovy may face generic competition on different timelines despite using the same molecule. A generic sponsor that wants to launch generic semaglutide injection for type 2 diabetes (referencing Ozempic) does not need the Wegovy formulation patents to expire; it needs the composition-of-matter and any Ozempic-specific Orange Book patents to expire or be successfully challenged.

What to watch: the FDA Orange Book listings under Ozempic NDA 209637, Wegovy NDA 215256, and Rybelsus NDA 213051. Each NDA has its own patent listing. The earliest expiration date among the patents listed for a given NDA is the practical generic-availability gate for that product — not the latest expiration. Paragraph-IV ANDA filers can challenge later-expiring patents on validity or non-infringement grounds, which is what unlocked liraglutide generics ahead of some Orange Book listings.

Tirzepatide (Mounjaro, Zepbound) — mid-to-late 2030s

Tirzepatide is a 39-amino-acid synthesized peptide acting as a dual GIP / GLP-1 receptor agonist. It is regulated under two separate NDAs: Mounjaro (type 2 diabetes, FDA approved May 2022) and Zepbound (chronic weight management, FDA approved November 2023). Both share the same molecule and the same Eli Lilly composition-of-matter patents.

Tirzepatide's patent estate runs noticeably deeper than semaglutide's for one simple reason: it was filed later. The original Lilly composition-of-matter patents on tirzepatide trace to applications in the mid-2010s. Standard 20-year term plus available patent-term extensions and pediatric exclusivity put the practical generic-availability gate in the mid-to-late 2030s. Lilly has also built a typical big-pharma patent thicket — formulation patents, dosing-regimen patents, manufacturing-process patents, and device patents on the autoinjector — that can extend the practical exclusivity window beyond core composition-of-matter expiration.

Practical implication: if the closest precedent for tirzepatide is the liraglutide generic timeline (Victoza brand approval January 2010, Hikma generic approval December 2024 — roughly 14 years; Saxenda brand approval December 2014, Teva generic approval August 2025 — roughly 11 years), then the earliest plausible generic tirzepatide window is 2033-2037 calendar years from Mounjaro's May 2022 approval. That is a decade-plus from now. For deeper coverage of just tirzepatide, see our companion article: When will there be a generic Zepbound? — tirzepatide-only deep dive.

Foundayo (orforglipron) — late 2030s

Foundayo is the trade name for orforglipron, Eli Lilly's small-molecule oral GLP-1 receptor agonist FDA-approved in April 2026 for chronic weight management. Unlike semaglutide and tirzepatide, orforglipron is not a peptide — it is a true small-molecule, non-peptide GLP-1 receptor agonist that survives oral absorption without the SNAC-style absorption enhancer Rybelsus relies on. That is chemically remarkable but it does not change the regulatory pathway: orforglipron is regulated under an NDA, so post-LOE it would face Hatch-Waxman generic competition.

Lilly's composition-of-matter patent estate on orforglipron is the youngest of the major branded GLP-1s, based on patent filings from the late 2010s. Standard 20-year term plus available extensions push the practical generic-availability window into the late 2030s. Orforglipron's small-molecule chemistry actually makes future generic competition easier than for the peptides: small-molecule manufacturing is cheaper and faster to scale than peptide synthesis with fatty-acid side-chain modification, so the lead time from patent expiration to first-generic launch should be shorter than for tirzepatide or semaglutide.

Why Trulicity is different (BLA biosimilar pathway)

Trulicity (dulaglutide) is the GLP-1 receptor agonist that breaks the pattern of every other drug in this article. Dulaglutide is a recombinant Fc-fusion protein — two GLP-1-analog peptides covalently linked via flexible peptide linkers to a modified human IgG4 Fc fragment. It is a true biologic. The FDA regulates it under a Biologics License Application (BLA), not an NDA. It is listed in the FDA Purple Book, not the Orange Book.

That has three immediate consequences:

• No Hatch-Waxman generics, ever. Follow-on dulaglutide products would be biosimilars, not generics. The pathway is 351(k) of the Public Health Service Act, not 351(j) of the Federal Food, Drug, and Cosmetic Act. They are not the same.
• Reference product exclusivity is 12 years. The Biologics Price Competition and Innovation Act (BPCIA) grants the originator 12 years of reference-product exclusivity from the date of BLA approval. Trulicity was BLA-approved in September 2014, so the 12-year BPCIA exclusivity expires in September 2026. That clears the path for filing 351(k) biosimilar applications. It does not mean a biosimilar is approved — FDA still has to grant approval, and that typically takes years after the application is filed.
• Biosimilars are not automatically interchangeable. A biosimilar is “highly similar” to the reference biologic with no clinically meaningful differences in safety, purity, or potency. To be substituted at the pharmacy counter without prescriber action, FDA must separately designate the biosimilar as interchangeable under 351(k)(4) — typically requiring a switching study showing no decrease in efficacy or increase in safety risk when patients alternate between reference and biosimilar.

As of 2026-05-09, no biosimilar dulaglutide has been FDA-approved or even publicly disclosed as filed. The most likely scenario is a 3-5 year post-LOE window before the first approved biosimilar, with interchangeability designation potentially taking longer.

Compounded GLP-1s are NOT generics

A note on terminology because patients hear “compounded semaglutide” and “generic semaglutide” used interchangeably in marketing copy. They are not the same thing.

• FDA-approved generic. An ANDA-approved drug. Therapeutically equivalent to the reference brand (AB-rated). Pharmacist substitution legal in every state subject to state pharmacy law. Manufactured under cGMP and backed by FDA-approved chemistry/manufacturing/controls (CMC) data. No FDA-approved generic semaglutide, tirzepatide, or orforglipron exists as of 2026-05-09.
• Compounded preparation. A drug prepared for a specific patient under a valid prescription by a state-licensed 503A pharmacy or by a 503B outsourcing facility. NOT FDA-approved. No CMC review by FDA. No FDA review of clinical efficacy or safety. No AB therapeutic-equivalence rating. Compounded preparations can still be made legally under section 503A or 503B of the FD&C Act when specific clinical conditions are met, but they are categorically distinct from generics.

2024-2026 enforcement context. FDA declared the semaglutide and tirzepatide drug shortages resolved in October 2024. Both molecules were removed from the FDA Drug Shortage List, which significantly narrowed the legal basis for bulk compounding under sections 503A(b)(1)(D) and 503B(a)(2). 503A pharmacies can still compound for individual patients with documented clinical justification (e.g., a documented allergy to a brand inactive ingredient), but mass-market “cheaper-than-brand” compounding for general weight-loss demand has lost its primary legal cover. Many 503A and 503B pharmacies continue to dispense compounded GLP-1s on regulatory theories — slightly modified peptide formulations (e.g., semaglutide + B12 or + cyanocobalamin), patient-specific clinical-need documentation, or pivots to non-GLP-1 weight-loss compounds. FDA has issued multiple Warning Letters in response. The legal status is unsettled.

For continuously updated coverage of where compounded semaglutide pricing and availability sit right now, see our cheapest compounded semaglutide tracker and 12-month compounded GLP-1 price-movement analysis. And for a verified-source overview of the FDA enforcement actions to date, see our FDA warning letters investigation.

What patent litigation typically delays

Even when the headline composition-of-matter patent expires, a generic launch is rarely instantaneous. The Hatch-Waxman framework gives originators several legal mechanisms to defer, narrow, or settle generic entry:

• Paragraph-IV certifications. Under the Hatch-Waxman framework, an ANDA filer can certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed by the proposed generic (a paragraph-IV certification). The originator has 45 days to sue. If they sue, an automatic 30-month stay typically delays FDA generic approval. Most paragraph-IV cases settle.
• 30-month stays. The automatic stay can be extended via successive patent listings or shortened by court order, but the default is 30 months from the date the originator sues. That alone can shift a generic launch by up to two and a half years from the composition-of-matter expiration date.
• Pediatric exclusivity (6 months). If the originator completes FDA-requested pediatric studies, FDA grants 6 months of additional exclusivity tacked onto the end of every Orange Book-listed patent and exclusivity term for the drug. Novo Nordisk has obtained pediatric exclusivity for at least one semaglutide indication, and Lilly is pursuing pediatric studies for tirzepatide.
• Orphan-drug exclusivity (7 years). Less relevant for major weight-management drugs, but becomes relevant if a sponsor pursues an orphan indication (rare disease) for a GLP-1 drug — for example, glucagon receptor activity tied to a rare metabolic disorder.
• Patent-term extension (PTE, up to 5 years). Originators can recapture FDA-review time lost during NDA approval via a single patent-term extension on one Orange Book-listed patent per drug, capped at the lesser of half the regulatory-review delay or 5 years, with a 14-year-from-approval ceiling. Both semaglutide and tirzepatide have or are expected to have PTE-extended composition-of-matter patents.
• Method-of-use patents. Even when composition-of-matter expires, originators commonly hold separate method-of-use patents covering specific indications, dosing regimens, or patient populations. Generic ANDA filers can “carve out” a method-of-use patent with a section 8 statement and obtain approval for the un-carved-out indications, but that strategy can fragment the generic label and reduce payer coverage.
• ANDA settlement agreements. Most paragraph-IV cases ultimately settle. Settlements can accelerate generic launch (a “launch authorization” before patent expiration) or defer it (a “reverse-payment” settlement, the subject of FTC scrutiny under FTC v. Actavis). The terms are typically confidential.

The takeaway: the calendar date when a brand drug “goes generic” in retail pharmacies is a legal-litigation outcome, not a clean patent-expiration moment. Industry analysts (Evaluate Pharma, IQVIA, manufacturer SEC disclosures) typically model a 2-3 year uncertainty window around any specific generic-launch forecast.

What this means for cash-pay patients (2026-2030)

For a cash-pay patient on Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound, or Foundayo today, the practical implications of the generic timeline above:

• Liraglutide 1.8 mg (Victoza generic, Hikma) is available now for type 2 diabetes patients. Cash pricing on generic Victoza has fallen substantially below brand. For weight management, the Saxenda generic (Teva, August 2025) is also now available — though daily injection liraglutide is generally considered less effective for weight loss than weekly semaglutide or tirzepatide per head-to-head trial data.
• No generic semaglutide or tirzepatide is coming before the early 2030s at the earliest. Cash-pay patients on Ozempic, Wegovy, Mounjaro, or Zepbound should not budget for a generic-driven price collapse in the next 5 years. The realistic price-relief levers between now and the patent cliff are: manufacturer self-pay programs (LillyDirect Self Pay Journey Program, NovoCare), mass-retailer cash channels (Sam's Club KwikPen, Costco), and — to the degree that the regulatory dust settles — compounded preparations from established 503A / 503B pharmacies.
• Foundayo (orforglipron) is the cheapest brand-name FDA-approved option in 2026 at $149/month via LillyDirect or Amazon Pharmacy. This is a structurally cheaper price point than any other brand-name GLP-1 weight-management option and is unlikely to fall much further until generic competition arrives in the late 2030s.
• Trulicity biosimilars are in a different cost curve than generics. Even when the first biosimilar dulaglutide arrives (sometime after 2027), the cost erosion will be more like 30-50% of the reference brand than the 80-90% small-molecule generics deliver. Biosimilars also typically launch with insurance coverage on a separate formulary tier than generics.
• Compounded GLP-1s are not a generic and the regulatory floor is moving. Pricing in our pricing index is updated continuously. The legal status of compounded semaglutide and tirzepatide post-October-2024 enforcement-discretion sunset is genuinely unsettled. Patients buying compounded GLP-1s right now should treat provider regulatory standing as a separate due-diligence line item.

Bottom line

• Two generic GLP-1 RAs are FDA-approved right now: Hikma generic liraglutide (Victoza, December 2024) and Teva generic liraglutide 3 mg (Saxenda, August 28, 2025). Plus Amneal generic exenatide (Byetta, November 21, 2024) for type 2 diabetes — though AstraZeneca discontinued the Byetta brand in October 2024.
• Wegovy, Ozempic, Rybelsus (semaglutide) generic competition is widely modeled in the early 2030s. The earliest reasonable cash-pay-relief window from generic semaglutide is 2031-2033, and the actual launch date depends on patent litigation, paragraph-IV certifications, pediatric exclusivity, and ANDA settlement agreements.
• Mounjaro and Zepbound (tirzepatide) generic competition runs into the mid-to-late 2030s. Lilly's tirzepatide patent estate is later-filed than Novo's semaglutide estate, so generic tirzepatide is structurally further out. Best-case window: 2036+.
• Foundayo (orforglipron) generic competition is even further out — late 2030s. Foundayo's patent estate is the youngest of the major branded GLP-1s.
• Trulicity (dulaglutide) is on a different pathway entirely. It is an Fc-fusion biologic on a BLA. Follow-on dulaglutide will be a 351(k) biosimilar, not a Hatch-Waxman generic. BPCIA reference-product exclusivity expires September 2026; first biosimilar approval is plausibly 3-5 years after that. Biosimilars do not erode brand price as fast as small-molecule generics.
• Compounded GLP-1s are NOT generics. They are not FDA-approved, are not therapeutically equivalent, and are not pharmacist-substitutable for brand-name drugs. The legal grace period that protected mass-market compounded semaglutide and tirzepatide ended in October 2024. The regulatory landscape is unsettled.
• Every patent date in this article is an estimate. Patent-term extensions, pediatric exclusivity, paragraph-IV litigation, and 30-month stays can move launch dates by years. Always verify against the FDA Orange Book + USPTO + each manufacturer's most recent annual report before relying on a specific date.

Related research

• When will there be a generic Zepbound? — tirzepatide-only deep dive — focused coverage of just tirzepatide, including the liraglutide-precedent calculation in detail.
• GLP-1 compounded pricing index 2026 — continuously updated cash-pay pricing distribution across every tracked compounded-GLP-1 provider.
• Is $99 compounded semaglutide real? — provider-by-provider verification of the floor-price tier in the compounded-semaglutide market.
• 12-month compounded GLP-1 price movement — how cash-pay compounded prices moved from January 2025 forward.
• FDA warning letters: GLP-1 compounding investigation — the live database of FDA enforcement actions against GLP-1 compounders since the October 2024 grace-period sunset.
• Foundayo vs Wegovy vs Zepbound — head-to-head — molecule, route, efficacy, and pricing comparison of the three FDA-approved weight-management GLP-1s most relevant to cash-pay patients in 2026.
• GLP-1 insurance coverage at the 10 largest US insurers — for patients deciding between insurance-covered brand name and cash-pay compounded.
• Wegovy GoodRx + cash-pay coupon channel guide — every legitimate cash-pay channel for Wegovy in 2026.